Skip to main content

Table 4 Treatment is displayed for each year in the 10-year period from 2008 to 2017 for patients with psoriatic arthritis monitored with outcome measures in an ordinary outpatient clinic

From: Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway

Treatment

2008 (n = 106)

2009 (n = 268)

2010 (n = 318)

2011 (n = 365)

2012 (n = 377)

2013 (n = 397)

2014 (n = 412)

2015 (n = 384)

2016 (n = 340)

2017 (n = 341)

Annual mean

P valuea2008–17 and 2013–17

No treatmentb (%)

29 (27.4)

92 (34.3)

96 (30.2)

115 (31.5)

115 (30.5)

112 (28.2)

113 (27.4)

102 (26.6)

72 (21.2)

65 (19.1)

27.5%

< 0.001 0.011

bDMARD (%)

32 (30.2)

63 (23.5)

88 (27.7)

99 (27.1)

113 (30.0)

120 (30.2)

129 (31.3)

125 (32.6)

107 (31.5)

112 (32.8)

29.9%

0.29 0.94

TNF inhibitor (%)

31 (29.2)

59 (22.0)

83 (26.1)

94 (25.8)

110 (29.2)

115 (29.0)

121 (29.4)

118 (30.7)

99 (29.1)

100 (29.3)

28.1%

0.43 0.99

Non-TNF inhibitors (%)

1 (0.9)

4 (1.5)

5 (1.6)

5 (1.4)

3 (0.8)

5 (1.3)

8 (1.9)

7 (1.8)

8 (2.4)

12 (3.5)

1.8%

0.32 0.30

sDMARD (%)

59 (55.7)

136 (50.7)

168 (52.8)

188 (51.5)

192 (50.9)

208 (52.4)

215 (52.2)

206 (53.6)

188 (55.3)

192 (56.3)

53.0%

0.89 0.75

One sDMARD (%)

59 (55.7)

136 (50.7)

168 (52.8)

188 (51.5)

191 (50.7)

208 (52.4)

214 (51.9)

205 (53.4)

188 (55.3)

191 (56.0)

52.8%

0.96 0.87

Two sDMARDs (%)

0 (0)

0 (0)

0 (0)

0 (0)

1 (0.3)

0 (0)

1 (0.2)

1 (0.3)

0 (0)

1 (0.3)

0.1%

–

bDMARD and sDMARD (%)

20 (18.9)

36 (13.4)

51 (16.0)

52 (14.2)

61 (16.2)

66 (16.6)

68 (16.5)

68 (17.7)

52 (15.3)

53 (15.5)

15.9%

0.91 0.91

TNF inhibitor and sDMARD (%)

20 (18.9)

35 (13.1)

50 (15.7)

52 (14.2)

61 (16.2)

64 (16.1)

65 (15.8)

64 (16.7)

49 (14.4)

47 (13.8)

15.3%

0.89 0.81

Prednisolone (%)

24 (22.6)

39 (14.6)

49 (15.4)

52 (14.2)

49 (13.0)

56 (14.1)

52 (12.6)

54 (14.1)

59 (17.4)

60 (17.6)

14.9%

0.22 0.23

Prednisolone and sDMARD (%)

16 (15.1)

23 (8.6)

29 (9.1)

32 (8.8)

26 (6.9)

28 (7.1)

25 (6.1)

28 (7.3)

31 (9.1)

31 (9.1)

8.1%

0.19 0.44

Prednisolone, sDMARD, and bDMARD (%)

4 (3.8)

8 (3.0)

9 (2.8)

7 (1.9)

5 (1.3)

9 (2.3)

5 (1.2)

5 (1.3)

5 (1.5)

5 (1.5)

1.9%

0.47 0.77

Biologic DMARDs

 Adalimumab (%)

11 (10.4)

31 (11.6)

41 (12.9)

44 (12.1)

46 (12.2)

48 (12.1)

44 (10.7)

41 (10.7)

25 (7.4)

28 (8.2)

10.9%

0.33 0.18

 Certolizumab (%)

0 (0)

0 (0)

0 (0)

1 (0.3)

1 (0.3)

1 (0.3)

12 (2.9)

16 (4.2)

18 (5.3)

15 (4.4)

1.9%

< 0.001 0.001

 Etanercept (%)c

8 (7.5)

20 (7.5)

26 (8.2)

37 (10.1)

44 (11.7)

33 (8.3)

34 (8.3)

31 (8.1)

30 (8.8)

34 (10.0)

9.0%

0.69 0.90

 Golimumab (%)

0 (0)

0 (0)

9 (2.8)

5 (1.4)

7 (1.9)

23 (5.8)

19 (4.6)

12 (3.1)

11 (3.2)

8 (2.3)

2.8%

< 0.001 0.11

 Infliximab (%)d

12 (11.3)

8 (3.0)

7 (2.2)

7 (1.9)

12 (3.2)

10 (2.5)

12 (2.9)

19 (4.9)

15 (4.4)

15 (4.4)

3.5%

0.001 0.31

 Abatacept (%)

1 (0.9)

4 (1.5)

4 (1.3)

2 (0.5)

2 (0.5)

4 (1.0)

2 (0.5)

2 (0.5)

1 (0.3)

1 (0.3)

0.7%

0.65 0.66

 Ustekinumab (%)

0 (0)

0 (0)

0 (0)

1 (0.3)

0 (0)

1 (0.3)

6 (1.5)

4 (1.0)

5 (1.5)

2 (0.6)

0.6%

0.022 0.33

 Sekukinumab (%)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

2 (0.6)

9 (2.6)

0.3%

< 0.001< 0.001

Other biologics (%)

0 (0)

0 (0)

1 (0.3)

2 (0.5)

1 (0.3)

0 (0)

0 (0)

1 (0.3)

0 (0)

0 (0)

0.2%

0.55 0.42

Synthetic DMARDs (%)

 Leflunomide

6 (5.7)

19 (7.1)

27 (8.5)

37 (10.1)

48 (12.7)

53 (13.4)

58 (14.1)

49 (12.8)

36 (10.6)

37 (10.9)

11.2%

0.037 0.52

 Methotrexate

48 (45.3)

106 (39.6)

124 (39.0)

134 (36.7)

130 (34.5)

144 (36.3)

151 (36.7)

147 (38.3)

141 (41.5)

149 (43.7)

38.5%

0.22 0.18

 Sulfasalazine

4 (3.8)

8 (3.0)

13 (4.1)

13 (3.6)

11 (2.9)

7 (1.8)

4 (1.0)

8 (2.1)

8 (2.4)

5 (1.5)

2.4%

0.16 0.62

 Other synthetic DMARDse

1 (0.9)

3 (1.1)

4 (1.3)

4 (1.1)

4 (1.1)

4 (1.0)

3 (0.7)

3 (0.8)

3 (0.9)

2 (0.6)

0.9%

1.00 0.98

Ever users

 Biologic DMARDs (%)

41 (38.7)

74 (27.6)

106 (33.3)

123 (33.7)

138 (36.6)

152 (38.3)

165 (40.0)

171 (44.5)

150 (44.1)

157 (46.0)

38.6%

< 0.001 0.16

 TNF inhibitor (%)

41 (38.7)

74 (27.6)

105 (33.0)

122 (33.4)

137 (36.3)

150 (37.8)

164 (39.8)

168 (43.8)

147 (43.2)

156 (45.7)

38.2%

< 0.001 0.17

 Non-TNF inhibitors (%)

2 (1.9)

5 (1.9)

8 (2.5)

7 (1.9)

7 (1.9)

11 (2.8)

16 (3.9)

17 (4.4)

21 (6.2)

20 (5.9)

3.4%

0.004 0.15

  1. Data are presented as n (%)
  2. bDMARD biologic disease-modifying antirheumatic drug, sDMARD synthetic disease-modifying antirheumatic drug, TNF tumor necrosis factor
  3. aχ2 test used to test for differences during follow-up for the period 2008–2017 and 2013–2017
  4. bNo prednisolone, bDMARD or sDMARD
  5. cIncludes the originator and SB4
  6. dIncludes the originator and the biosimilar CT-P13
  7. eIncludes hydroxychloquine, auranofin, azathioprine
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us